Viral Genetics in 2012 — Research Update

by Kris_Tuttle on March 7, 2012

We recently com­pleted a new research update on Viral Genet­ics which is a very small quasi-public com­pany emerg­ing from a quiet year with much more planned in 2012. [Click to access the PDF of our Viral Update Report March 6, 2012.]

Since we pub­lished the report just a day or two ago the com­pany announced their first Pre-IND sub­mis­sion to the FDA for the treat­ment of Lyme Dis­ease. The com­pany has also pub­lished some of their plans for the year in their recent let­ter to share­hold­ers which is avail­able via this link (PDF).

As noted in our research update and prior research reports Viral Genet­ics has strong fun­da­men­tal sci­ence that has broad appli­ca­tions in med­i­cine and even energy. The com­pany has built a strong patent port­fo­lio sup­port­ing two dis­tinct plat­form tech­nolo­gies (Meta­bolic Dis­rup­tion and Tar­geted Pep­tides) since 1994.  Besides devel­op­ing appli­ca­tions them­selves they are also work­ing on licens­ing their core patents to be used in dif­fer­ent drug therapies.

To do all this the com­pany is actively seek­ing cap­i­tal and inter­ested investors should con­tact the com­pany directly for more infor­ma­tion. As they begin to spend more time in the clinic and attract devel­op­ment and licens­ing part­ners we believe they will find an eas­ier time attract­ing cap­i­tal and can improve their bal­ance sheet and ratio­nal­ize their share cap­i­tal. This is after all a long-term invest­ment story suit­able to institutions.

[We have advised the com­pany on strat­egy and investor posi­tion­ing but are not in any way work­ing with them on struc­tur­ing their financ­ing or pro­mot­ing it to investors. We have eval­u­ated the sci­ence and the prospec­tive appli­ca­tions only. No infor­ma­tion pro­vided should be relied upon by any­one in mak­ing an invest­ment deci­sion. We are not a broker/dealer or invest­ment bank and are mak­ing no solicitation.]

Comments on this entry are closed.

Previous post:

Next post: